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Extraneural pathologic prion protein in sporadic
Creutzfeldt-Jakob disease
Abstract
BACKGROUND: In patients with sporadic Creutzfeldt-Jakob disease, pathologic disease-associated
prion protein (PrPSc) has been identified only in the central nervous system and olfactory-nerve tissue.
Understanding the distribution of PrPSc in Creutzfeldt-Jakob disease is important for classification and
diagnosis and perhaps even for prevention. METHODS: We used a highly sensitive method of
detection--involving the concentration of PrPSc by differential precipitation with sodium
phosphotungstic acid, which increased the sensitivity of Western blot analysis by up to three orders of
magnitude--to search for PrPSc in extraneural organs of 36 patients with sporadic Creutzfeldt-Jakob
disease who died between 1996 and 2002. RESULTS: PrPSc was present in the brain tissue of all
patients. In addition, we found PrPSc in 10 of 28 spleen specimens and in 8 of 32 skeletal-muscle
samples. Three patients had PrPSc in both spleen and muscle specimens. Patients with extraneural
PrPSc had a significantly longer duration of disease and were more likely to have uncommon molecular
variants of sporadic Creutzfeldt-Jakob disease than were patients without extraneural PrPSc.
CONCLUSIONS: Using sensitive techniques, we identified extraneural deposition of PrPSc in spleen
and muscle samples from approximately one third of patients who died with sporadic Creutzfeldt-Jakob
disease. Extraneural PrPSc appears to correlate with a long duration of disease.
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background
 
In patients with sporadic Creutzfeldt–Jakob disease, pathologic disease-associated pri-
on protein (PrP
 
Sc
 
) has been identified only in the central nervous system and olfactory-
nerve tissue. Understanding the distribution of PrP
 
Sc
 
 in Creutzfeldt–Jakob disease is
important for classification and diagnosis and perhaps even for prevention.
 
methods
 
We used a highly sensitive method of detection — involving the concentration of PrP
 
Sc
 
by differential precipitation with sodium phosphotungstic acid, which increased the
sensitivity of Western blot analysis by up to three orders of magnitude — to search for
PrP
 
Sc
 
 in extraneural organs of 36 patients with sporadic Creutzfeldt–Jakob disease who
died between 1996 and 2002.
 
results
 
PrP
 
Sc
 
 was present in the brain tissue of all patients. In addition, we found PrP
 
Sc
 
 in 10 of
28 spleen specimens and in 8 of 32 skeletal-muscle samples. Three patients had PrP
 
Sc
 
in both spleen and muscle specimens. Patients with extraneural PrP
 
Sc
 
 had a significantly
longer duration of disease and were more likely to have uncommon molecular variants
of sporadic Creutzfeldt–Jakob disease than were patients without extraneural PrP
 
Sc
 
.
 
conclusions
 
Using sensitive techniques, we identified extraneural deposition of PrP
 
Sc
 
 in spleen
and muscle samples from approximately one third of patients who died with sporadic
Creutzfeldt–Jakob disease. Extraneural PrP
 
Sc
 
 appears to correlate with a long duration
of disease.
abstract
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rion diseases are characterized by
 
degeneration of central nervous tissue asso-
ciated with the replication of a transmissi-
ble agent, a prion.
 
1
 
 Prions are mainly composed
of an abnormal, partially protease-resistant con-
former (PrP
 
Sc
 
) of a cellular protein (PrP
 
C
 
).
 
2
 
 Although
tissue damage occurs only in the central nervous
system, the accumulation of PrP
 
Sc
 
 and prion infec-
tivity are not necessarily confined to neural tissue
in all prion diseases. In scrapie in sheep, chronic
wasting disease in deer, and numerous animal mod-
els of prion diseases, prions invade the lympho-
reticular system.
 
3
 
 PrP
 
Sc
 
 has also been reported in the
skeletal muscle of mice with experimentally induced
prion disease.
 
4
 
The most common prion disease in humans is
Creutzfeldt–Jakob disease, which has been classi-
fied as sporadic, familial, iatrogenic, or variant. The
causation of sporadic Creutzfeldt–Jakob disease is
unclear, whereas biochemical, histopathological,
and epidemiologic evidence suggests that the vari-
ant form results from the transmission of bovine
spongiform encephalopathy prions to humans.
 
5,6
 
PrP
 
Sc
 
 accumulates in tonsils
 
7
 
 and other lymphore-
ticular organs
 
8
 
 of patients with variant Creutzfeldt–
Jakob disease,
 
9
 
 whereas the sporadic form of the
disease is not thought to target the lymphoreticu-
lar system.
 
10
 
 The allegedly unique involvement of
the lymphoreticular system in variant Creutzfeldt–
Jakob disease serves as a diagnostic criterion to dis-
tinguish variant from sporadic Creutzfeldt–Jakob
disease and is one of the principal pieces of evidence
that these forms represent two distinct disease en-
tities.
 
6
 
 Refinements in the sensitivity of the meth-
ods of detection
 
11
 
 prompted us to reinvestigate
the distribution of PrP
 
Sc
 
 in humans with sporadic
Creutzfeldt–Jakob disease.
 
collection of samples
 
We collected central nervous system, spleen, and
muscle samples at autopsy from a cohort of Swiss
patients who died between 1996 and 2002: 36 pa-
tients with prion disease (36 brain specimens, 32
muscle specimens, and 28 spleen specimens), 10
with Alzheimer’s disease (10 muscle and 8 spleen
samples), and 9 patients without neurologic disor-
ders (9 muscle and 9 spleen samples). The utmost
care was taken to avoid contamination of extraneu-
ral samples with central nervous system tissue. All
tissues were processed according to established
guidelines regarding safety and ethics.
 
detection of p
 
r
 
p
 
Sc
 
 in extraneural tissues
 
All procedures were carried out in biosafety level
3 facilities with strict adherence to safety guide-
lines. The method of precipitation with the use of
sodium phosphotungstic acid was adapted from
published protocols.
 
8
 
 We prepared 10 percent tis-
sue homogenates (weight per volume) in 2 percent
sarkosyl in sterile phosphate-buffered saline using
a RiboLyser (Hybaid). Cellular debris was removed
by centrifugation at 80¬
 
g
 
 for one minute in a micro-
centrifuge. Occasional residual debris was removed
by additional centrifugation at 2700¬
 
g
 
 for five min-
utes. Supernatants (500 µl) were mixed with equal
volumes of 2 percent sarkosyl in phosphate-buf-
fered saline and incubated for 10 minutes at 37°C.
Benzonase (Benzon nuclease, Merck) and magne-
sium chloride were added (final concentration, 50
units per milliliter and 1 mmol per liter, respective-
ly), and the mixture was incubated under constant
agitation for 30 minutes at 37°C.
Samples were adjusted to a final concentration
of 0.3 percent phosphotungstate, incubated at 37°C
for 30 minutes under constant agitation, and cen-
trifuged at 15,800¬
 
g
 
 for 30 minutes in a microcen-
trifuge. The pellets were resuspended in 20 µl of
phosphate-buffered saline with 0.1 percent sarko-
syl. Samples were adjusted to a final concentration
of 20 µg of proteinase K per milliliter and incubat-
ed at 37°C for 30 minutes. Digestion was terminat-
ed by the addition of protease inhibitors (Complete
protease inhibitor cocktail, Boehringer Mannheim).
Samples were boiled in loading buffer (125 mM
TRIS sodium chloride, 4 percent sodium dodecyl
sulfate, 20 percent glycerol, and 0.02 percent bro-
mophenol blue), subjected to electrophoresis in 12
percent TRIS–glycine gels, and blotted on nitrocel-
lulose membranes. Membranes were blocked with
5 percent Topblock (Jura) in phosphate-buffered sa-
line with 0.05 percent Tween and then incubated
overnight with a monoclonal antibody against PrP
(3F4; dilution 1:5000).
 
12
 
 
The samples were then incubated with an alka-
line-phosphatase–conjugated secondary antibody
(1:20,000) and examined with use of 2-chlor-
5-(4-methoxyspiro{1,2-dioxetan-3,2'-(5'-chlor)
tricycl[3.3.1.13,7]decan}-4-yl)-1-phenylphosphate
dinatrium salt chemiluminescent substrate (Amer-
sham) and a VersaDoc digital imager (model 5000,
p
methods
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Bio-Rad). Each blot included appropriate positive
and negative controls (10 µg or 100 µg of brain ho-
mogenate from a patient with sporadic Creutzfeldt–
Jakob disease or a patient without a prion disease
added to 50 mg of muscle or spleen specimen from
a patient without a prion disease). All analyses were
carried out and all but six samples were examined at
least twice by independent investigators. Samples
were deemed positive if proteinase K–resistant di-
glycosylated, monoglycosylated, and unglycosylat-
ed bands with electrophoretic motility indicative
of PrP
 
Sc
 
 were unambiguously identified.
 
detection of p
 
r
 
p
 
Sc
 
 in neural tissues
 
Western blot analysis was carried out as described
previously.
 
13
 
 PrP glycoforms were quantified with
use of a Kodak image station (model 440) or a Versa-
Doc digital imager (model 5000), and patients were
typed according to the size of the protease-resist-
ant core PrP fragment
 
14
 
 and the prevalence of glyco-
forms.
 
15,16
 
genetic analysis
 
Genomic DNA was extracted from frozen tissues.
Polymerase chain reaction and analysis of the en-
tire coding region of the prion protein gene (
 
PRNP
 
)
were performed with use of standard techniques
and software (SeqScape, Applied Biosystems). In
addition, codon 129 polymorphisms were identi-
fied by restriction-fragment–length polymorphism
analysis.
 
17
 
histologic analysis
 
Tissue was fixed with 4 percent buffered formalin,
inactivated by exposure to 98 percent formic acid
for one hour, and embedded in paraffin. Sections
(3 µm) were subjected to conventional staining and
to immunostaining for glial fibrillary acid protein
(Dako) and PrP (monoclonal antibody 3F4) after hy-
drolytic autoclaving.
We analyzed a total of 45 spleen specimens and 51
skeletal-muscle samples from 36 patients with his-
topathologically, biochemically, and genetically con-
firmed sporadic Creutzfeldt–Jakob disease (mean
[
 
±
 
SD] age, 66.8
 
±
 
8.7 years; 20 men and 16 women);
10 patients with Alzheimer’s disease (mean age,
76.2
 
±
 
4.6 years; 6 men and 4 women); and 9 patients
without neurologic disease (mean age, 59
 
±
 
19.2
years; 5 men and 4 women). The age distribution,
sex ratio, and duration of disease (mean, 5.0
 
±
 
4.6
months) of the cohort of patients with sporadic
Creutzfeldt–Jakob disease did not differ significantly
from those in published series.
 
18
 
accumulation of p
 
r
 
p
 
Sc
 
 in spleen
and skeletal muscle
 
Western blot analysis of protease-resistant pri-
on protein after phosphotungstate precipitation
showed PrP
 
Sc
 
 in 10 of 28 spleen samples and in 8 of
32 skeletal-muscle samples from the patients with
sporadic Creutzfeldt–Jakob disease (Fig. 1). Three
patients had PrP
 
Sc
 
 in both spleen and muscle (Ta-
ble 1). Assays were repeated with independently ho-
mogenized tissue fragments: three spleen and three
muscle samples always tested positive, whereas oth-
ers yielded variable results (Table 1), possibly be-
cause of inhomogeneous peripheral distribution of
PrP
 
Sc
 
, as described previously.
 
4,19
 
Control samples of spleen and muscle were as-
sessed in parallel: none of them contained PrP
 
Sc
 
(data not shown). Patients with PrP
 
Sc
 
 in spleen and
patients without PrP
 
Sc
 
 in spleen did not differ sig-
nificantly with respect to age (Table 2). However,
patients with PrP
 
Sc
 
 only in spleen or in spleen or
muscle or both had significantly longer intervals
between the onset of clinical symptoms and death
than did patients without extraneural PrP
 
Sc
 
. Patients
with PrP
 
Sc
 
 in muscle tended to be younger at death
than patients without PrP
 
Sc
 
 in muscle (Table 2).
None of the subgroups differed significantly with
respect to the ratio of men to women.
One patient with splenic PrP
 
Sc
 
 had received a ca-
daveric dura mater transplant more than 22 years
before the onset of dementia. This case was deemed
unlikely to represent iatrogenic transmission, since
the incubation period would be longer than that in
any other documented case of dura mater–associ-
ated transmission.
 
20
 
genetic analysis of 
 
prnp
 
We sequenced the entire open reading frame of
 
PRNP
 
 from all patients with extraneural PrP
 
Sc
 
 and
found no disease-associated mutations. The com-
mon methionine–valine polymorphism at codon
129 was analyzed in all 10 patients with splenic
PrP
 
Sc
 
 and all 8 patients with muscle PrP
 
Sc
 
 as well as
in 15 patients without splenic PrP
 
Sc
 
 and 21 patients
without muscle PrP
 
Sc
 
. We observed a tendency to-
ward overrepresentation of heterozygosity for me-
thionine and valine and homozygosity for valine
among patients with splenic PrP
 
Sc
 
, whereas the ma-
results
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jority of patients with muscle PrP
 
Sc
 
 were homozy-
gous for methionine (Table 2).
 
histologic and biochemical analyses
 
Typical histopathological features of sporadic
Creutzfeldt–Jakob disease, consisting of spongiform
changes, neuronal loss, and gliosis, were present in
all patients (Fig. 2). The electrophoretic mobility of
unglycosylated, protease-digested PrP
 
Sc
 
 (also called
the core fragment size, which can be 21 kD for type
1 or 19 kD for type 2)
 
14
 
 allows for the stratification
of Creutzfeldt–Jakob disease into subgroups with
specific clinical features, which may be caused by dif-
ferent prion strains.
 
6
 
 A finer degree of stratification
is attained by including information on the codon
129 genotype and patterns of cerebral deposition
of PrP
 
Sc
 
; accordingly, we assigned each patient in
our series to one of seven proposed groups.
 
18
 
 This
analysis indicated an overrepresentation of uncom-
mon variants of sporadic Creutzfeldt–Jakob disease
such as MM2C (homozygous for methionine, type 2,
with cortical deposition) and MV2 (heterozygous,
type 2) in patients with extraneural PrP
 
Sc
 
 (Table 2),
suggesting that peripheral deposition of PrP
 
Sc
 
 may
identify a biochemically or genetically unique sub-
group of patients.
 
* Up to four individual fragments of each organ were independently homoge-
nized, subjected to phosphotungstate precipitation, and analyzed by Western 
blotting. Variability in detection may be due to inhomogeneous distribution of 
 
PrP
 
Sc
 
 in extraneural organs. ND denotes not done.
 
Table 1. Age at Onset and Duration of Disease in 15 Patients with Sporadic 
Creutzfeldt–Jakob Disease and Extraneural Pathologic Prion Protein (PrP
 
Sc
 
).
Patient
No. Age
Duration
of Disease
Location of 
Extraneural PrP
 
Sc
 
Muscle* Spleen*
 
yr mo no. with PrP
 
Sc
 
/total no.
 
1 47 7 Spleen 0/2 1/4
2 48 6 Muscle 2/2 ND
3 52 6 Spleen ND 1/2
4 55 8 Spleen 0/2 1/3
5 60 5 Spleen and muscle 1/2 1/1
6 62 3 Muscle 1/2 0/1
7 65 29 Muscle 1/3 ND
8 66 3 Muscle 1/2 0/2
9 67 7 Spleen and muscle 1/2 3/3
10 68 4 Muscle 2/2 0/2
11 68 7 Spleen 0/2 2/4
12 73 5 Spleen and muscle 1/1 2/2
13 77 3 Spleen 0/2 2/3
14 77 4 Spleen 0/2 1/3
15 81 5 Spleen 0/2 1/3
 
Figure 1. Western Blot Analysis of Phosphotungstate-Precipitated Pathologic Prion Protein (PrP
 
Sc
 
) from Spleen and Muscle Samples 
from Patients with Sporadic Creutzfeldt–Jakob Disease (sCJD).
 
Lanes 1 and 2 show Western blot (total protein) analysis of 50 µg of brain homogenate from a patient without Creutzfeldt–Jakob disease. 
Lanes 3 and 4 show brain homogenate from a patient with sporadic Creutzfeldt–Jakob disease diluted with spleen homogenate from a patient 
without a prion disease (control); lanes 5 and 6 brain homogenate from a control diluted with spleen homogenate from a control; lanes 7 and 
8 spleen homogenate from a patient with sporadic Creutzfeldt–Jakob disease; and lanes 9, 10, 11, 12, and 13 muscle homogenate from a pa-
tient with sporadic Creutzfeldt–Jakob disease. PrP
 
Sc
 
 is present in two samples (lanes 7 and 10). Lanes 2, 4, and 6 through 13 show results 
after proteinase K digestion.
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Quantification of the relative prevalence of di-
glycosylated, monoglycosylated, and unglycosylat-
ed PrP
 
Sc
 
 is a further instrument for the biochemi-
cal characterization of PrP
 
Sc
 
, which allows one to
discriminate sporadic from variant Creutzfeldt–
Jakob disease.
 
16
 
 This analysis did not uncover any
unorthodox PrP
 
Sc
 
 glycotypes in patients with pe-
ripheral PrP
 
Sc
 
 (Fig. 3): the distribution of brain gly-
cotypes in patients with peripheral PrP
 
Sc
 
 was similar
to that in other cohorts of patients with sporadic
Creutzfeldt–Jakob disease.
 
13
 
distribution of p
 
r
 
p
 
Sc
 
 in skeletal-muscle 
groups
 
Earlier studies in mice have shown that the PrP
 
Sc
 
content may vary among muscle groups.
 
4
 
 In our
series, the presence of PrP
 
Sc
 
 was not limited to spe-
cific muscle groups: PrP
 
Sc
 
 was found in four sam-
ples of pectoral muscle, two samples of psoas mus-
cle, and two samples of intercostal muscle. It was
absent in 10 pectoral-muscle specimens, 5 psoas-
muscle specimens, 2 biceps-muscle specimens, and
4 intercostal-muscle specimens. In three patients
without extraneural PrP
 
Sc
 
, no information on the
anatomical origin of muscle samples could be ob-
tained.
 
quantification of p
 
r
 
p
 
Sc
 
 in extraneural 
organs
 
In order to estimate the relative concentration of
PrP
 
Sc
 
 in extraneural organs, we compared the inten-
sity of proteinase K–digested Western blot signals
with calibration curves obtained by diluting brain
homogenate from a patient with Creutzfeldt–Jakob
disease with muscle or spleen homogenate from a
patient without a prion disease. Despite consider-
able variations in individual spleen and muscle spec-
imens, the signal intensity of peripheral PrP
 
Sc
 
 was
generally similar to that obtained when 10 µg of
brain homogenate from a patient with sporadic
Creutzfeldt–Jakob disease was diluted with 50 mg
of spleen or muscle from a patient without a prion
disease (Fig. 1). Therefore, we estimate that the lev-
els of PrP
 
Sc
 
 in extraneural organs are lower by a fac-
tor of approximately 1¬10
 
¡4
 
 than those typically
found in the central nervous system of patients with
sporadic Creutzfeldt–Jakob disease.
Previous studies did not detect PrP
 
Sc
 
 in the tonsils,
spleen, lymph nodes,
 
10 or appendix of patients
with sporadic Creutzfeldt–Jakob disease.21 How-
discussion
* Plus–minus values are means ±SD. Data on classification are from Parchi et al.14,18 Mann–Whitney tests were used for 
all comparisons of age and the duration of illness. Sex ratios were compared with use of chi-square tests. Only significant 
differences between groups are indicated.
† Patients were classified according to the size of the protease-resistant fragment of PrPSc (type 1 [21 kD] or type 2 [19 kD]), 
whether they were homozygous for methionine (MM1, MM2C, or MM2T) or valine (VV1P or VV2) at codon 129 of the 
prion gene or were heterozygous (MV1 or MV2), and histologic characteristics such as plaque or plaque-like lesions (P), 
cortical or synaptic deposits (C), and thalamic deposits (T).
‡ P=0.004.
§ Patients with no available information on codon 129 were not classified.
¶P=0.003.
Table 2. Demographic Characteristics and Classification of Sporadic Creutzfeldt–Jakob Disease in Patients 
with and Those without Pathologic Prion Protein (PrPSc) in Spleen and Muscle Specimens.*
Status of Peripheral PrPSc Disease Phenotype† Sex Age
Duration
of Disease
MM1 MV1 VV1P MM2C MM2T MV2 VV2
no. of patients M/F yr mo
Spleen sample
PrPSc present
PrPSc absent§
3
12
1
1
1 1
1
2
1
2 5/5
11/7
65.9±6.9
67.9±6.9
5.7±1.6‡
4.0±2.2‡
Muscle sample
PrPSc present
PrPSc absent§
5
14 2 1
2
3
1
1
4/4
15/9
63.6±7.4
67.6±8.8
7.7±8.7
4.4±2.3
Spleen or muscle sample
PrPSc present
PrPSc absent§
7
15
1
1
1 2 2
1
2 7/8
13/8
64.4±10.5
68.6±7.0
6.8±6.3¶
3.8±2.2¶
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ever, after a systematic search for PrPSc in extraneu-
ral organs of patients referred to the Swiss National
Reference Center for Prion Diseases, we found that
extraneural deposits of PrPSc are much more fre-
quent in patients with sporadic Creutzfeldt–Jakob
disease than previously thought. There may be sev-
eral reasons why this fact was not previously rec-
ognized.
First, our series of patients is much larger than
previous ones. Second, repeated homogenization of
distinct fragments of extraneural organs identified
substantial variations in the PrPSc content of these
tissues. Generic problems related to the technical
reproducibility of our results are unlikely to account
for this variation, since control samples consist-
ing of brain homogenate from a patient with spo-
radic Creutzfeldt–Jakob disease diluted with mus-
cle or spleen homogenate from a patient without
a prion disease did not have such variations (data
not shown). Instead, the presence of variability sug-
gests that the distribution of PrPSc is not homoge-
neous in single muscle fibers and single splenic ger-
minal centers. This finding parallels the finding that
prion infectivity titers vary in spleen22 and muscle4
samples from experimentally infected mice.
Third, PrPSc levels in spleen and muscle were
lower than those in brain by a factor of 1¬10¡4: ex-
traneural PrPSc was never detectable by plain West-
ern blot analysis (data not shown) and could be vis-
ualized only after sodium phosphotungstic acid
precipitation, an approach that increases the sen-
sitivity of Western blot analysis by three orders of
magnitude by preferentially precipitating PrPSc from
tissue homogenates.8,11 Although this method is
not suitable for use with very small biopsy speci-
mens (less than 100 mg), it is ideal for situations in
which sample size is not a limiting factor.
Previous studies suggested the presence of ab-
normal PrP in the skeletal muscle of patients with
inclusion-body myositis.23 However, this may rep-
resent denervation-dependent up-regulation of PrPC
transcription.24 In one patient with coincident spo-
radic Creutzfeldt–Jakob disease and inclusion-body
myositis, we found PrPSc levels that were 103 times
as high as the levels in our study cohort, possibly
because the overexpression of PrPC in muscle facil-
itates the deposition of PrPSc (Kovacs G: personal
communication).
Does the presence of peripheral PrPSc correlate
with any specific genetic, biochemical, or clinical
Figure 2. Histopathological Findings in the Cerebellum of Patients with Sporadic Creutzfeldt–Jakob Disease and Peripheral Pathologic Prion 
Protein (PrPSc).
Deposition of PrPSc in the cerebellum was diffuse, granular, and synaptic in a patient who was homozygous for methionine at codon 129 of the 
prion protein gene (MM1 and MM2C [Panels A and D]) and in one who was heterozygous (MV1 [Panel B]). Deposition of PrPSc was in the 
form of plaques and plaque-like lesions in patients who were homozygous for valine at codon 129 (VV1P [Panel C] or VV2 [Panel F]) and in one 
who was heterozygous (MV2 [Panel E]).18 IGL denotes internal granule-cell layer, PCL Purkinje-cell layer, and ML molecular layer.
IGL
PCL
ML
20 µm MV1MM1
MV2 VV2
VV1P
MM2C
A B C
D E F
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factors? When plotting the incidence of codon 129
polymorphisms (MM, MV, or VV [homozygous for
valine]), PrPSc core-fragment sizes (type 1, 21 kD,
and type 2, 19 kD), and histologic characteristics
(plaque and plaque-like lesions [P], cortical or syn-
aptic deposits [C], or thalamic deposits [T]), we ob-
served several uncommon phenotypes in patients
with peripheral PrPSc, such as MM2C and MV2. In
addition, one patient with PrPSc in lymphoid organs
who was homozygous for valine at codon 129 could
not be classified according to any of the existing
schemes.18,25 These features may represent a new
phenotype with atypical clinical signs,26 which
we have termed VV1P because of the presence of
plaque-like deposits of PrP in the cerebellum and
a PrPSc core-fragment size of 21 kD.
The relative ratios of PrPSc glycoforms are dif-
ferent in sporadic and variant Creutzfeldt–Jakob
disease. Glycotype analysis failed to reveal features
specific to patients with peripheral PrPSc, and none
of them had the glycoform distribution associated
with variant Creutzfeldt–Jakob disease. Patients with
splenic PrPSc had significantly longer durations of
disease than did those without splenic PrPSc. As-
suming that prions arise primarily in the central
nervous system of these patients, one might specu-
late that protracted disease increases the likelihood
of spillover of cerebral PrPSc to extraneural areas.
Figure 3. Glycoform Profiles of Patients with Sporadic and Variant Creutzfeldt–Jakob Disease (CJD) According to 
the Presence or Absence of Peripheral Pathologic Prion Protein (PrPSc).
The triangular plot correlates the intensities of the diglycosylated (upper), monoglycosylated (middle), and unglycosylat-
ed (lower) bands of PrPSc. Study patients with sporadic Creutzfeldt–Jakob disease and PrPSc in spleen, muscle, or both; 
study patients with sporadic Creutzfeldt–Jakob disease but no PrPSc in spleen or muscle; and British control patients with 
sporadic Creutzfeldt–Jakob disease (black, dark gray, and light gray boxes) cluster in the same area of the plot. Instead, 
control patients with variant Creutzfeldt–Jakob disease (white square13) are segregated in a distinct region of the plot.
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Although the amount of PrPSc found in spleen
and muscle samples from patients with sporadic
Creutzfeldt–Jakob disease was much lower than lev-
els in lymphoid organs of patients with variant
Creutzfeldt–Jakob disease,7 and the infectivity of
prions from these tissues awaits verification, our
findings arouse concern about the possibility of iat-
rogenic transmission of sporadic Creutzfeldt–Jakob
disease. Brown et al. reported that extraneural tis-
sues of patients with spongiform encephalopathy
(including hereditary forms and kuru) occasion-
ally transmitted disease when inoculated into non-
human primates.27 Infectivity was detected in 2 of
4 lung-tissue samples, 4 of 35 liver specimens, 5 of
28 kidney specimens, 3 of 31 spleen samples, and
3 of 15 lymph-node samples.27 Five attempts to
transmit the disease through the inoculation of skel-
etal muscle were not successful, possibly because
the sample size was insufficient, because the infec-
tivity of the samples was not uniform, or because
transmission from human to nonhuman primates
is not always highly efficient.
The causation of sporadic Creutzfeldt–Jakob dis-
ease is unknown. Some allegedly sporadic cases may
in reality have an iatrogenic origin, and surgery of
any kind was found to constitute a mild risk factor
for sporadic Creutzfeldt–Jakob disease.28 Extensive
epidemiologic surveys did not substantiate any risk
of blood-borne transmission,29 suggesting that the
presence of PrPSc in lymphoid organs whose cellu-
lar constituents migrate to and from blood may not
lead to substantial contamination of blood dona-
tions by prions.
Many patients with sporadic Creutzfeldt–Jakob
disease are subjected to extensive neurologic exam-
inations in the prodromal stages, often including
electromyography and muscle biopsies. The finding
that PrPSc is prevalent in skeletal muscle reinforces
calls for the use of single-use needle electrodes and
of special protocols for the sterilization of surgical
instruments used for muscle biopsies.
Our results suggest that muscle and lymph-node
biopsies can be used as diagnostic procedures for
sporadic Creutzfeldt–Jakob disease. Because of the
unambiguous and extremely specific nature of the
immunochemical detection of PrPSc, any positive
results would firmly establish the diagnosis of
Creutzfeldt–Jakob disease without the need for more
invasive procedures. However, the diagnostic sen-
sitivity of the detection of PrPSc in muscle-biopsy
specimens is likely to be low, since less than one
third of our patients were positive for PrPSc in mus-
cle. We did not detect PrPSc in one muscle-biopsy
specimen obtained because of suspected vasculitis
10 weeks before death in a patient with Creutzfeldt–
Jakob disease (data not shown). The sensitivity of
prion detection is likely to improve soon, in view of
the considerable refinements in the technique that
are being reported.30
In contrast to previous reports, our study fo-
cused on a homogeneous, narrowly defined group
of patients. All the patients had died of sporadic
Creutzfeldt–Jakob disease in Switzerland between
1996 and 2002. On the other hand, there has been an
alarming increase in the incidence of Creutzfeldt–
Jakob disease in Switzerland.13 Although the caus-
es of this epidemiologic shift are not clear, the etio-
logic process of sporadic Creutzfeldt–Jakob disease
in our cohort may differ from that in cohorts in oth-
er countries. It will therefore be important to extend
the present study to additional countries, in order to
determine whether our observations apply to all cas-
es of sporadic Creutzfeldt–Jakob disease.
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